SynthesisEuropean journal of medical research2021
A fresh look at the role of spiramycin in preventing a neglected disease: meta-analyses of observational studies.
Synthesis in European journal of medical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- [Use of antiparasitic drugs in the prevention of congenital toxoplasmosis: systematic review and meta-analysis].Medecine tropicale et sante internationale · 2025Pooled it
- Antiparasitic activity of peppermint and lavender essential oil nano-emulsions against Toxoplasma gondii RH strain in vitro and in vivo.Veterinary research communications · 2026Article
- Diverse chemotypes of polyketides as promising antimicrobial agents: latest progress.RSC advances · 2025Review
- Karakum desert: a unique source of cultivable novel and rare actinomycetes with a remarkable biosynthetic potential.World journal of microbiology & biotechnology · 2025Article
- Treatment Protocols for Gestational and Congenital Toxoplasmosis: A Systematic Review and Meta-Analysis.Microorganisms · 2025Review
- Risk of Congenital Toxoplasmosis in Newborns from Mothers with Documented Infection: Experience from Two Referral Centres.Pathogens (Basel, Switzerland) · 2025Observational
- REIV-TOXO Project: Results from a Spanish cohort of congenital toxoplasmosis (2015-2022). The beneficial effects of prenatal treatment on clinical outcomes of infected newborns.PLoS neglected tropical diseases · 2024Observational
- In defense of children's brain: reshuffling the laboratory toolbox for the diagnosis of congenital toxoplasmosis.Journal of clinical microbiology · 2024Article
- Anti-Inflammatory Effects of Spiramycin in LPS-Activated RAW 264.7 Macrophages.Molecules (Basel, Switzerland) · 2022Article
- Building Programs to Eradicate Toxoplasmosis Part I: Introduction and Overview.Current pediatrics reports · 2022Review
- Building Programs to Eradicate Toxoplasmosis Part IV: Understanding and Development of Public Health Strategies and Advances "Take a Village".Current pediatrics reports · 2022Review
- The anti-Frontiers in veterinary science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe aimed to investigate the effect of antepartum treatment with spiramycin with or without subsequent pyrimethamine-sulfonamide-folinic acid, compared to no treatment, on the rate of mother-to-child transmission (MTCT) of Toxoplasma gondii (T. gondii) and incidence/severity of sequelae in the offspring.
methodsEmbase and PubMed were searched for literature on spiramycin in pregnant women suspected/diagnosed with T. gondii infection. Meta-analyses were performed using random-effects model.
resultsThirty-three studies (32 cohorts and 1 cross-sectional study), with a total of 15,406 mothers and 15,250 offspring, were pooled for analyses. The MTCT rate for all treated patients was significantly lower than the untreated [19.5% (95% CI 14-25.5%) versus 50.7% (95% CI 31.2-70%), p < 0.001]. The transmission rate in patients on spiramycin monotherapy was also significantly lower than untreated [17.6% (95% CI 9.9-26.8%) versus 50.7% (95% CI 31.2-70%), p < 0.001].
conclusionResults indicate significant reduction in MTCT rates following spiramycin treatment of suspected/diagnosed maternal T. gondii infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.